GUIDELINES CATEGORY 1 FOR 1L PATIENTS

Experts discuss the National Comprehensive Cancer Network^® (NCCN^®) Category 1 Preferred 1L treatment options

There is controversy on the choice of CDK4/6i as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.  
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

EFFICACY ACROSS TRIALS

An expert discusses proven overall survival across 3 phase III trials in patients with HR+/HER2- mBC

Dr Gabriel Hortobagyi discusses proven overall survival with KISQALI across 3 phase III trials.

START & STAY

Expert perspective on dosing and patient adherence in HR+/HER2- mBC

Dr Nick McAndrew shares his perspective on simple dose reductions with KISQALI and how to improve adherence in patients with HR+/HER2- mBC.

ROUND TABLE DISCUSSIONS

Round table discussion: Managing QT interval and ECG assessments

Drs Dent, Guha, and Moore discuss a hypothetical premenopausal patient with HR+/HER2- mBC. The team discusses managing QT interval and ECG assessments when starting the patients on KISQALI, as well as managing them throughout treatment.

Round table discussion: Addressing DDIs

Drs Dent, Guha, and Moore discuss a hypothetical postmenopausal patient with HR+/HER2- mBC. The team addresses potential drug-drug interactions with medications the patient is currently taking to manage other conditions.

Round table discussion: Addressing cardiac comorbidities 

Drs Dent, Guha, and Moore discuss a hypothetical postmenopausal patient with HR+/HER2- mBC with preexisting cardiac conditions, how these may factor into her treatments, and the best method for starting treatment with KISQALI.